glp-1 for mash Incretin-based therapies in MASLD/MASH: from receptor agonists to dual and triple agonists Indications for GLP-1/GIP RA Summary
Description
Patients typically begin at the lower dose and ramp up to the highest dose over roughly a month
US FDA Disclaimer The products and the claims made about specific products on or through this document have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure or prevent disease
Shorter-acting agents like liraglutide and exenatide may require a shorter washout, often around 4 weeks, depending on the clinical situation
If body weight is dropping quickly and protein intake is inconsistent, strength may feel more variable at first
Overall odds ratios from the random effects model (3.44) and common effect model (3.40) indicate that ROSE-010 is significantly better than a placebo ( Figure 5 )
